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Abstract
Pathway analysis of genome-wide association studies (GWAS) offer a unique opportunity to collectively evaluate
genetic variants with effects that are too small to be detected individually. We applied a pathway analysis to a bladder
cancer GWAS containing data from 3,532 cases and 5,120 controls of European background (n = 5 studies). Thirteen
hundred and ninety-nine pathways were drawn from five publicly available resources (Biocarta, Kegg, NCI-PID,
HumanCyc, and Reactome), and we constructed 22 additional candidate pathways previously hypothesized to be
related to bladder cancer. In total, 1421 pathways, 5647 genes and ,90,000 SNPs were included in our study. Logistic
regression model adjusting for age, sex, study, DNA source, and smoking status was used to assess the marginal trend
effect of SNPs on bladder cancer risk. Two complementary pathway-based methods (gene-set enrichment analysis
[GSEA], and adapted rank-truncated product [ARTP]) were used to assess the enrichment of association signals within
each pathway. Eighteen pathways were detected by either GSEA or ARTP at P#0.01. To minimize false positives, we
used the I2 statistic to identify SNPs displaying heterogeneous effects across the five studies. After removing these
SNPs, seven pathways (‘Aromatic amine metabolism’ [PGSEA = 0.0100, PARTP = 0.0020], ‘NAD biosynthesis’ [PGSEA = 0.0018,
PARTP = 0.0086], ‘NAD salvage’ [PARTP = 0.0068], ‘Clathrin derived vesicle budding’ [PARTP = 0.0018], ‘Lysosome vesicle
biogenesis’ [PGSEA = 0.0023, PARTP,0.00012], ’Retrograde neurotrophin signaling’ [PGSEA = 0.00840], and ‘Mitotic
metaphase/anaphase transition’ [PGSEA = 0.0040]) remained. These pathways seem to belong to three fundamental
cellular processes (metabolic detoxification, mitosis, and clathrin-mediated vesicles). Identification of the aromatic
amine metabolism pathway provides support for the ability of this approach to identify pathways with established
relevance to bladder carcinogenesis.
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Introduction
Genome-wide association studies (GWAS) have served as a
useful tool to identify common genetic variants associated with
various complex traits [1]. As expected, each variant explains a
tiny portion of the heritable component of their associated
phenotypes [2,3]. Recently, Park and colleagues estimated that
some proportion of the ‘missing heritability’ may reside in
additional common low-penetrance susceptibility variants that
can be discovered in larger GWAS [4]. In principle, other
methods could complement the primary single-locus tests of
GWAS in identifying additional susceptibility loci. One such
approach is pathway (gene-set) analysis [5,6], which examines
whether association signals of a collection of functionally related
loci (typically genes) consistently deviate from what is expected
by chance. This approach may suggest new candidate
susceptibility loci and possibly provide insights into the
mechanisms underlying complex traits. Pathway-based analyses
have been applied to GWAS of complex diseases, including
multiple sclerosis [7], type-2 diabetes [8,9], Crohn’s disease
[10,11], Parkinson’s disease [12,13], colon [14] and breast [15]
cancers.
Bladder cancer is the fourth most common malignancy among
men in the western world [16]. Epidemiological studies have
shown that exposure to aromatic amines (AAs) from tobacco
smoking or occupation is strongly associated with bladder cancer
risk [16,17,18,19]. Additionally, genetic studies have demon-
strated that functional polymorphisms in two genes involved in
carcinogen metabolism (N-acetyltransferase 2 [NAT2] and
glutathione S-transferase M1 [GSTM1]) are associated with
bladder cancer risk [20,21]. Notably, the risk of bladder cancer
associated with NAT2 slow acetylation genotype is restricted to
smokers [20,22]. Recently, a series of GWAS have identified
previously unknown susceptibility loci for bladder cancer, with
the prospects of more to be discovered [22,23,24,25]. To identify
additional regions that harbor plausible candidate genes and
shed further light on genetic basis of this disease, we applied
pathway analysis to the first stage of the NCI’s CGEMS bladder
cancer GWAS containing 3,532 cases and 5,120 controls [22].
We report here seven pathways implicated in diverse carcino-
genic processes to be enriched with bladder cancer susceptibility
loci.
Materials and Methods
Study population
We applied our analyses to primary scan data of 591,637 SNPs
from NCI’s bladder cancer GWAS containing 3,532 cases and
5,120 controls of European ancestry from five studies (Spanish
Bladder Cancer Study [SBCS], New England, Maine and
Vermont Bladder Cancer Study [NEBCS-ME/VT], Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study [ATBC],
the American Cancer Society Cancer Prevention Study II
Nutrition Cohort [CPS-II], and the Prostate, Lung, Colorectal
and Ovarian Cancer Screening Trial [PLCO]) [22].
Pathway data construction
We collected gene-sets from five publicly available pathway
resources: BioCarta [26], Kyoto Encyclopedia of Genes and
Genomes (KEGG) [27], NCI’s Pathway Interaction Database
(PID) [28], Reactome [29], and Encyclopedia of Homo sapiens
Genes and Metabolism (HumanCyc) [30]. Inclusion criteria of
pathways for analysis were those containing 5–100 genes to avoid
testing too narrowly- or too broadly- defined functional categories.
In addition, we constructed 22 candidate pathways (Table S2)
based on known bladder cancer risk factors and general
carcinogenic processes [31,32,33] which were not represented in
the public databases above. Specifically, selection of genes was
determined through 1) biochemical data for the detoxification of
aromatic amines [34,35]; 2) Ingenuity pathway lists [36]; and 3)
Gene ontology lists [37].
To explore the similarity between pathways in our database, we
assessed the percentage of overlapping genes between each two
pathways (A and B) as:
Overlap(%)~
(
N½A\B
N½A|B
z
N½A\B
minfNA,NBg )
2
|100% ð1Þ
where NA and NB are the number of genes within pathways A and
B.
SNPs from the first stage of the NCI bladder cancer GWAS
[22] were mapped to genes in these pathways if they were located
in a region encompassing 20 kb 59 upstream and 10 kb 39
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downstream from the genes’ coding regions (NCBI’s human
genome build 36.3). These gene’s boundaries were selected
attempting to capture most of the gene’s coding and regulatory
variants [38] as well as minimizing the overlap between genes.
Overall, 1,422 pathways containing 5,647genes (24.3621.7
[mean 6 SD] genes per pathway) and ,92,000 SNPs were
included in our database. A complete list of the studied pathways
is available in Table S1.
Statistical analysis
SNPs with MAF,1% among controls were excluded from the
analysis. We fitted logistic regression models adjusted for age, sex,
study center, DNA source (buccal/blood), and smoking status
(current/former/never/occasional), to assess the marginal effect of
each SNP (1 degree of freedom trend test) on the risk of bladder
cancer, as previously described [22]. For each gene Gj (j=1, …, N,
where N is the total number of genes in our dataset), the SNP with
the lowest p-value among all SNPs that were mapped to its region
was selected to represent the gene in the pathway analysis. We
used two approaches to test for overrepresentation of association
signals within pathways in our database:
A. Gene-set enrichment analysis (GSEA; [12]): In this approach,
the 2log10 of the p-value of each gene’s best SNP was used
as the gene’s test statistics (rj=2log10(pj). Then, a weighted
Kolmogorov-Smirnov procedure was used to assess for
overrepresentation of gene’s statistics Enrichment Score (ES)
within each pathway (S) [15].
ESs~ max
1ƒjƒN
f
X
Gj[S,jƒj
rj
 
Ws
{
X
Gj=[S,jƒj
1
N{NH
g ð2Þ
where, WS~
P
Gj[S
rj
  and NH is the number of genes in a
pathway.
A. The statistical significance of ESS was empirically evaluated
using 10,000 permutations (permuting the genotype data
between individuals and keeping the LD between SNPs
intact).
B. Adaptive Rank-Truncated Product (ARTP; [39]): In this
approach the genes’ best SNP p-values (pj) in each pathway
were ordered from lowest to highest. Then, the mathematical
product was computed for all possible sets of p(j) such that
W (K)~ P
K
j~1
(p(j)) ð3Þ
with K, 1#K#L, being all possible integers (the truncation
points) between 1 and L, with L being the number of genes in
a pathway. In words, W(K) is simply the product of the K
smallest P-values in a pathway. Next, we used the minP
statistics [40,41] to evaluated what is the K truncation point
where the W(K) get the most statistically significant value.
minP~ min
1ƒjƒJ
s
^
(Kj) ð4Þ
where s
^
(Kj) be the estimated P-value for W(Kj), K1#…#K.
B. We then used two-level permutation procedure (10, 000
permutations, permuting the genotype data between individ-
uals and keeping the LD structure between SNPs intact) to
estimate s
^
(Kj), and to adjust for multiple testing over the
different truncation points used.
Using both the GSEA and ARTP methods that employ
different approaches to assess the enrichment of gene-based
signals within predefined gene-sets may facilitate capturing a
broader range of candidate pathways for bladder cancer
susceptibility.
Finally, we calculated a false discovery rate (FDR) to assess the
proportion of expected false positive findings in the GSEA and
ARTP analyses. In short, we normalized the GSEA and ARTP
statistics for each pathway (NSs(GSEA) and NSs(ARTP) respectively)
based on the mean and standard deviation of the corresponding
permutation data [12]. This procedure allows a direct compar-
ison of pathways with different sizes and gene compositions.
Then, we used these normalized statistics to calculate the FDR
as:
FDR~
Pper
S NS
per
S §NSSPper
S NS
per
S
=
P
S NSS§NSSP
S NSS
ð5Þ
Genetic heterogeneity analysis
To minimize false positives, we estimated the I-squared statistic
(I2) [42] to identify SNPs displaying heterogeneous effects across
the five studies [ATBC, CPSII, NEBCS (ME, VT), PLCO, and
SBCS]. I2describes the proportion of total variation in study
estimates that is due to heterogeneity. In short, a meta-analysis was
applied to every SNP belonging to one of the top pathways using
the genotype frequency counts of cases and controls to estimate
per-allele OR and CI’s. SNPs with I2 P-values,0.2 were removed
from further analyses. We evaluated the OR, CI and p values for
both the meta-analysis and they were similar in both models, and
did not change the interpretation of the data. These analyses were
done using STATA (Version 11, STATA Corporation, College
Station, TX).
Results
Overall, there was good correlation between the results of the
GSEA and the ARTP methods (r = 0.74, P,0.0001). A detailed
examination of the results revealed that, on average, GSEA
performed better in detecting pathways enriched with multiple
weak association signals while ARTP appeared to be more
powerful in detecting pathways where only few genes with
relatively strong signals are dominating. Notably, the AA
metabolism pathway, which contains several known bladder
cancer susceptibility loci, was detected by both GSEA and ARTP
methods (PGSEA=0.0100, PARTP=0.0020). Therefore, we used its
significance level as a reference for highlighting additional
candidate susceptibility pathways. Of the 1421 pathways exam-
ined, 18 were significantly enriched with association signals at the
P,0.01 level (Table 1). Of these, seven pathways were detected by
both GSEA and ARTP, four pathways were detected only by
GSEA, and seven were detected only by ARTP. After removing
SNPs with heterogeneous effects across the five studies (I2 P-
value,0.2), the enrichment signals remained significant (P,0.01)
in seven pathways belonging to four cellular processes (‘‘aromatic
amine [AA] metabolism’’, ‘‘Nicotinamide adenine dinucleotide
[NAD] metabolism’’, ‘‘Clathrin-mediated vesicles’’, and ‘‘Mito-
sis’’). For clarity, from this point forward, we will refer only to the
results from the post heterogeneity analysis.
Pathway Analysis of Bladder Cancer GWAS
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Aromatic amine [AA] metabolism
Table 2 displays the results for the genes in the AA pathway.
The enrichment signals in this pathway were mainly driven by
SNPs in the UGT1A9 and NAT2 genes. SNPs in these genes were
identified in the primary analysis of this GWAS [22]. Removing
these two genes from the pathway analyses reduced the
enrichment signal in the AA metabolism pathway in both methods
but still ranked it relatively high using the GSEA (PGSEA=0.0130,
PARTP=0.1217). Apart from UGT1A9 and NAT2, five additional
genes in this pathway had SNPs with significant genetic effect
(Ptrend,0.05). These included NAT1, UGT1A4, UGT1A6, NQO1
and CYP1B1.
Some of the genes in the AA metabolism pathway (i.e. CYP1A1
and CYP1A2; UGT1A4, UGT1A6 and UGT1A9; SULT1A1 and
SULT1A2) occur on the same chromosomal locus and conse-
quently share similar tagging SNPs. To assess the effect of this
redundancy on the pathway enrichment signal, we pooled together
genes with overlapping SNPs and treated them as a single genetic
unit in our pathway analyses. Consequently, the number of loci
included in the AA metabolism pathway was reduced to seven,
(Table S2) and the corresponding enrichment signals were
strengthened (PGSEA=0.0046, PARTP=0.0001). Even when remov-
ing the NAT2 and UGT1A regions from this gene-set, its cor-
responding enrichment signal remains relatively high (PGSEA=
0.024, PARTP=0.0921).
NAD metabolism
Two nicotinamide adenine dinucleotide (NAD) metabolism
pathways were detected in this analysis. The ‘‘NAD biogenesis I’’
pathway (HumanCyc) was detected by both GSEA and ARTP
(PGSEA=0.0018, PARTP=0.0086), and the ‘‘NAD salvage II’’
pathway (HumanCyc) was detected only by the ARTP method
(PARTP=0.0068). Table 3 presents the results for the genes in these
pathways. The three NMNAT genes (NMNAT1, NMNAT2, and
NMNAT3) that are shared by both of these two pathways harbor
SNPs with significant genetic effect (Ptrend,0.05) and therefore
likely to dominate the significant enrichment signals in these
pathways. Other genes displaying significant bladder cancer risk
are QPRT in the ‘‘NAD I’’ pathway, and ACP6, ITGB1BP3,
ACPL2 in the ‘‘NAD II’’ pathway.
Vesicle biogenesis and budding
Three pathways involved in clathrin-dependent vesicle biogen-
esis and budding were detected in this analysis. The ‘‘Lysosome
Vesicle Biogenesis’’ pathway (Reactome) showed the strongest
enrichment signal among all pathways in this study, and was
detected by both GSEA and ARTP (PGSEA=0.0023,
PARTP,0.0001). The ‘‘Clathrin derived vesicle budding’’ pathway
(Reactome) was detected only by ARTP (PARTP=0.0018), while
the ‘‘Retrograde neurotrophin signaling’’ pathway (Reactome) was
detected only by GSEA (PGSEA=0.0084). Table 4 displays the
Table 1. Pathways enriched with bladder cancer susceptibility loci at a P#0.01 level using GSEA and ARTP.
GSEA ARTP
Gene
overlap
(%)
Pathway source
#
genes1 # genes2 p-value3 FDR4 # genes2 p-value3 FDR4
Aromatic amine metabolism Self 11 (5); 1 (0.0059); 0.0100 (.0.5) (9); 1 (0.0012); 0.0020 (0.28) NA
NAD biosynthesis I (from aspartate) HumanCyc 5 (4); 4 (0.0021); 0.0018 (.0.5) (4); 4 (0.0086); 0.0086 (0.36) 44%
NAD salvage pathway II HumanCyc 9 (5); 6 (0.0150); 0.0583 (.0.5) (7); 8 (0.0033); 0.0068 (0.32)
Clathrin derived vesicle budding Reactome 15 (6); 6 (0.0210); 0.0189 (.0.5) (9); 9 (0.0018) 0.0018 (0.35)
Lysosome Vesicle Biogenesis Reactome 10 (6); 7 (0.0031); 0.0023 (.0.5) (7); 7 (,0.0001);
,0.0001
(0.16) 49%
Retrograde neurotrophin signaling Reactome 9 (4); 4 (0.0092); 0.0084 (.0.5) (4) ;4 (0.0192); 0.0192 (0.41)
Mitotic Metaphase/Anaphase Transition Reactome 8 (3); 3 (0.0043); 0.0040 (.0.5) (3); 3 (0.0187); 0.0187 (0.43) 55%
Mitotic Prometaphase Reactome 80 (12); 12 (0.0955); 0.2567 (.0.5) (13); 12 (0.0095); 0.0346 (0.37)
Control of skeletal myogenesis by hdac and
calcium/calmodulin-dependent kinase (camk)
BioCarta 21 (11); 10 (0.1216); 0.2322 (.0.5) (7); 3 (0.0040); 0.0617 (0.29) 12%
B cell receptor signaling pathway KEGG 75 (29); 28 (0.1121); 0.1931 (.0.5) (10); 9 (0.0059); 0.0244 (0.38)
Syndecan-1-mediated signaling events PID 15 (12); 9 (0.0014); 0.0388 (.0.5) (12); 11 (0.0092); 0.1666 (0.43) 18%
Syndecan-2-mediated signaling events PID 31 (19); 16 (0.0048); 0.0559 (.0.5) (31); 31 (0.0078); 0.1404 (0.42)
TGF-beta signaling pathway KEGG 85 (41); 36 (0.0090); 0.0988 (.0.5) (57); 57 (0.0251); 0.2196 (.0.5) NA
Activated AMPK stimulates fatty-acid
oxidation in muscle
Reactome 8 (4); 3 (0.0434); 0.2470 (.0.5) (8); 8 (0.0017); 0.0454 (0.41)
AMPK inhibits chREBP transcriptional activity Reactome 5 (3); 2 (0.0010); 0.0411 (.0.5) (3); 2 (0.0014); 0.0465 (0.33) 39%
Reversal of insulin resistance by leptin BioCarta 10 (5); 7 (0.0170); 0.6432 (.0.5) (10); 2 (0.0028); 0.1635 (0.37)
Maturity onset diabetes of the young KEGG 25 (12); 11 (0.0067); 0.0308 (.0.5) (12); 16 (0.0390); 0.1908 (.0.5) NA
Metabolism of polyamines Reactome 12 (6); 4 (0.0055); 0.0460 (.0.5) (7); 5 (0.0040); 0.0657 (0.32) NA
Results of the top ranked pathways (P,0.01) using GSEA and ARTP. In parenthesis are results prior of removal SNPs displaying heterogeneous signals.
1The number of genes in the pathway.
2The number of genes underlying the enrichment signal in the pathway.
3P-value of the enrichment score based on 10,000 permutations.
4False-discovery rate calculated based on the normalized statistics of the permutation data to account for the variable sizes of genes and pathways.
doi:10.1371/journal.pone.0029396.t001
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results for the genes in these pathways. Three genes are shared by
the three pathways: CLTA and CLTC, which encode for the light
and heavy chains of clathrin respectively, and SH3GL2 which is
associated with clathrin-mediated endocytosis. The association of
SNPs in these three genes with bladder cancer risk ranked them
among the top four genes in these pathways.
Mitosis
The ‘‘Mitotic metaphase/anaphase transition’’ (Reactome)
was detected by the GSEA method (PGSAE= 0.0040) and was
marginally significant using ARTP (PARTP=0.0187). Interesting-
ly, all eight genes in this pathway are included in the more
comprehensive ‘‘Mitotic prometaphase’’ pathway that was
detected in the initial pathway screening, but had a less
significant signal after removing SNPs with heterogeneous
signals (Table 1). Results for the eight genes included in the
‘‘Mitotic metaphase/anaphase transition’’ pathway are present-
ed in Table 5. Three SNPs in three genes (FBXO5, SMC3 and
SPC24) were associated with significant protective effect on
bladder cancer (Ptrend,0.05).
Table 3. Summary of genes in the NAD metabolism pathways used for pathway-based analysis of multi-study bladder cancer
GWAS.
Pathway Gene # SNPs1 SNP2 SNP3 rank MAF4 Allelic OR (95% CI)5 P-value6
NAD1/NAD2 NMNAT3 36 rs7636269 1 0.48 1.12 1.05 1.20 0.0004
NAD2 ACP6 16 rs1344 1 0.41 1.11 1.04 1.18 0.0017
NAD1 QPRT 7 rs3862476 1 0.07 1.19 1.04 1.35 0.0087
NAD1/NAD2 NMNAT2 36 rs4652795 1 0.38 0.92 0.86 0.98 0.0099
NAD1/NAD2 NMNAT1 8 rs1220398 1 0.14 0.89 0.81 0.98 0.0169
NAD2 ITGB1BP3 8 rs2304191 1 0.11 1.11 1.01 1.23 0.0355
NAD2 ACPL2 31 rs3210458 2 0.09 1.12 1.00 1.25 0.0421
NAD2 NUDT12 5 rs371315 1 0.28 1.07 1.00 1.15 0.0686
NAD2 NT5C3L 6 rs9907244 1 0.43 0.95 0.89 1.01 0.1094
NAD1 NADSYN1 17 rs4945007 1 0.06 1.10 0.96 1.25 0.1555
NAD2 C9orf95 19 rs7021664 1 0.08 0.94 0.83 1.06 0.3193
1Number of SNPs genotyped in the gene region (20 kb 59 upstream and 10 kb 39 downstream from the gene’s coding region).
2The SNP representing the gene in the pathway analysis after the removal of SNPs with heterogeneous effects.
3The rank of the SNP among all SNPs in the gene’s region based on their p-values.
4Minor allele frequency among controls.
5Per allele odds ratios +95% confidence intervals from logistic regression models adjusting for age, sex, study center, DNA source , and smoking.
61 d.f. trend test.
doi:10.1371/journal.pone.0029396.t003
Table 2. Summary of genes in the aromatic amine metabolism pathway used for pathway-based analysis of multi-study bladder
cancer GWAS.
Gene # SNPs1 SNP2
SNP3
rank MAF4
Allelic OR (95%
CI)5 P-value6
UGT1A9 72 rs11892031 1 0.08 0.77 0.68 0.87 3.661025
NAT2 15 rs4646249 1 0.28 0.89 0.83 0.95 0.0013
NAT1 11 rs9650592 1 0.11 0.86 0.78 0.96 0.0054
UGT1A4 41 rs4148328 1 0.38 0.91 0.85 0.98 0.0086
UGT1A6 62 rs4148328 1 0.38 0.91 0.85 0.98 0.0086
NQO1 6 rs1437135 1 0.20 0.91 0.84 0.99 0.0275
CYP1B1 13 rs2855658 1 0.43 0.94 0.88 1 0.0477
CYP1A1 4 rs2472297 2 0.22 1.03 0.95 1.11 0.4758
CYP1A2 5 rs2472297 4 0.22 1.03 0.95 1.11 0.4758
SULT1A1 1 rs1968752 1 0.37 1.01 0.95 1.08 0.7321
SULT1A2 1 rs4788073 1 0.37 0.99 0.93 1.06 0.8344
1Number of SNPs genotyped in the gene region (20 kb 59 upstream and 10 kb 39 downstream from the gene’s coding region).
2The SNP representing the gene in the pathway analysis after the removal of SNPs with heterogeneous effects.
3The rank of the SNP among all SNPs in the gene’s region based on their p-values.
4Minor allele frequency among controls.
5Per allele odds ratios +95% confidence intervals from logistic regression models adjusting for age, sex, study center, DNA source , and smoking.
61 d.f. trend test.
doi:10.1371/journal.pone.0029396.t002
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Discussion
Our pathway-based analysis of a large bladder cancer GWAS
using two complementary pathway-based methods (GSEA and
ARTP) identified an overrepresentation of association signals in
seven pathways (‘Aromatic amine metabolism’, ‘NAD biosynthe-
sis’, ‘NAD salvage’, ‘Clathrin derived vesicle budding’, ‘Lysosome
vesicle biogenesis’, ‘Retrograde neurotrophin signaling’, and
‘Mitotic metaphase/anaphase transition’) and suggest involvement
in at least three cellular processes (metabolic detoxification,
mitosis, and clathrin-mediated vesicles).
The identification of the AA metabolism pathway in this study by
both GSEA and ARTP could be considered a good indication for
the utility of this approach, since AA metabolism has established
relevance to bladder cancer susceptibility. Interestingly, the
enrichment signal in this pathway is driven by variations in the
UGT1A gene cluster and theNAT1,NAT2, andNQO1 genes (Table 1)
that are involved in detoxification processes in the AA pathway
[34,35]. The strong enrichment signal left in this pathway even after
the removal of the UGT1A and NAT2 genes from the analysis
indicates that other genetic variations affecting aromatic amines
detoxification may contribute to bladder cancer susceptibility.
The detection of the NAD metabolism pathway may be relevant
to bladder cancer susceptibility through several carcinogenic
mechanisms. First, NAD homeostasis has been shown to play a
role in various redox reactions that may lead to irreversible cellular
damage and consequently to the initiation of malignant tumor
[43]. In addition, NAD has been shown to be involved in DNA
repair and telomere maintenances [44] as well as in energy
production both of which are important processes in cancer
development. Interestingly, NAD metabolism pathway has been
implicated in a recent pathway-based analysis of colon cancer
GWAS [14]. Colon and bladder cancers have been associated with
NAT2 acetylation status. For bladder cancer, in which N-
acetylation is a detoxification step, NAT2 slow acetylator
phenotype presents a higher risk. In contrast, for heterocyclic
amine-related colon cancer in which N-acetylation is negligible
and O-acetylation is a carcinogen-activation step, NAT2 rapid
acetylator phenotype presents a higher risk [45]. Thus, similar
metabolic pathways could play diverse roles in the etiology of these
two cancers.
Three clathrin-mediated vesicle pathways are also highlighted
in this study. Clathrin-coated vesicles play essential role in
intracellular trafficking, endocytosis, and exocytosis [46]. In this
realm, it has been shown that clathrin-mediated vesicle pathways
regulate the signaling and cellular localization of several growth
factors [47] that are known to play a role in cancer susceptibility.
Interestingly, clathrin may be also relevant to the Mitotic
Metaphase/Anaphase transition pathway that was also implicated
in this study. During mitosis, clathrin helps stabilizing the
Table 4. Summary of genes in the Clathrin-mediated vesicle pathways used for pathway-based analysis of multi-study bladder
cancer GWAS.
Pathway Gene # SNPs1 SNP2
SNP3
rank MAF4 Allelic OR (95% CI)5 P-value6
Clathrin/Lysosome/Retrograde CLTA 10 rs10972786 1 0.06 1.27 1.11 1.45 0.0004
Clathrin/Lysosome ARRB1 29 rs667791 1 0.39 1.11 1.04 1.19 0.0014
Clathrin/Lysosome/Retrograde SH3GL2 92 rs2209426 1 0.17 0.87 0.80 0.95 0.0020
Clathrin/Lysosome/Retrograde CLTC 10 rs7224631 1 0.09 1.19 1.06 1.32 0.0023
Clathrin/Lysosome DNAJC6 38 rs1325607 1 0.21 1.12 1.03 1.21 0.0057
Clathrin/Lysosome HSPA8 8 rs11218950 1 0.05 0.80 0.68 0.95 0.0087
Retrograde NGF 45 rs12760036 1 0.10 0.85 0.76 0.96 0.0096
Clathrin/Lysosome AP1G1 7 rs9932707 1 0.45 1.07 1.00 1.14 0.0353
Clathrin VAMP2 3 rs3202848 1 0.37 0.93 0.86 1.00 0.0572
Clathrin VAMP8 9 rs719023 1 0.39 0.94 0.88 1.00 0.0631
Retrograde DNAL4 7 rs738141 1 0.17 1.08 1.00 1.18 0.0645
Clathrin SNAP23 3 rs4924682 1 0.01 1.27 0.95 1.70 0.1087
Clathrin/Lysosome DNM2 16 rs4804528 1 0.43 0.95 0.89 1.02 0.1437
Retrograde DNM1 13 rs13285411 1 0.12 0.93 0.84 1.03 0.1463
Clathrin/Lysosome AP1B1 14 rs5763140 1 0.11 1.08 0.97 1.19 0.1500
Clathrin/Lysosome ARF1 4 rs3768331 1 0.38 1.05 0.98 1.12 0.1536
Clathrin GBF1 15 rs1057050 1 0.06 0.90 0.78 1.04 0.1673
Retrograde NTRK1 13 rs1888861 1 0.23 0.95 0.88 1.03 0.2275
Retrograde AP2A2 12 rs7483870 1 0.23 0.96 0.89 1.04 0.3014
Retrograde AP2A1 9 rs2286948 1 0.36 1.03 0.96 1.10 0.3694
Clathrin STX4 1 rs10871454 1 0.39 1.00 0.94 1.07 0.9722
1Number of SNPs genotyped in the gene region (20 kb 59 upstream and 10 kb 39 downstream from the gene’s coding region).
2The SNP representing the gene in the pathway analysis after the removal of SNPs with heterogeneous effects.
3The rank of the SNP among all SNPs in the gene’s region based on their p-values.
4Minor allele frequency among controls.
5Per allele odds ratios +95% confidence intervals from logistic regression models adjusting for age, sex, study center, DNA source, and smoking.
61 d.f. trend test.
doi:10.1371/journal.pone.0029396.t004
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kinetochore fibers which are required for the proper function of
the mitotic spindle [48]. Thus, the overrepresentation of
association signals in two distinct pathways associated with mitosis
suggest that perturbations in the mitotic process, and particularly
those related to the metaphase/anaphase transition, may modify
the risk of human bladder cancer.
Strengths of our study are the large sample size; the use of
primary scan data from five independent studies allowing us to
address consistency of effects across the different populations; and
the use of two complementary pathway-based methods. A limitation
of our study is the lack of pathway-based signals to reach a
noteworthy FDR significance level, with only one pathway
(Lysosome Vesicle Biogenesis) having an FDR value ,0.2. This
could be partially due to the inherent limits of the methods used, the
inadequate annotation of relevant pathways in public databases, or
due to weak association signals in our data. Recent analysis of
bladder cancers using RNA expression data, have also highlighted
enrichment of genes with similar processes as we identified in our
genomic data here, including metabolic processes, which provide
further plausibility that the pathways identified may be relevant to
bladder cancer susceptibility [49]. Furthermore, the high rank of the
AA metabolism pathway in both GSEA and ARTP support the
power of these methods to highlight pathways with established
relevance to bladder cancer susceptibility and may therefore
similarly suggest the involvement of metabolic detoxification,
mitosis and clathrin-mediated pathways in bladder carcinogenesis.
Supporting Information
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